News
VANI
1.160
0.00%
0.000
Weekly Report: what happened at VANI last week (1216-1220)?
Weekly Report · 3d ago
Vivani Medical: Strategic Innovation in GLP-1 Obesity Treatment Justifies Buy Rating
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Vivani Medical (VANI) and Merit Medical Systems (MMSI)
TipRanks · 5d ago
Vivani reports start of first human trial of GLP-1 implant, says H.C. Wainwright
TipRanks · 5d ago
VIVANI MEDICAL INC: ANTICIPATES THAT TOP-LINE DATA WILL BE AVAILABLE IN MID-2025
Reuters · 12/19 13:30
EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia
Benzinga · 12/19 13:00
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
Barchart · 12/19 07:30
Weekly Report: what happened at VANI last week (1209-1213)?
Weekly Report · 12/16 11:35
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Benzinga · 12/13 16:16
Weekly Report: what happened at VANI last week (1202-1206)?
Weekly Report · 12/09 11:34
'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape
Benzinga · 12/03 17:11
Weekly Report: what happened at VANI last week (1125-1129)?
Weekly Report · 12/02 11:34
Weekly Report: what happened at VANI last week (1118-1122)?
Weekly Report · 11/25 11:25
*Vivani Medical Unit Cortigent Expects IPO of 1.5M Shrs to Price at $10 Each
Dow Jones · 11/20 22:25
Weekly Report: what happened at VANI last week (1111-1115)?
Weekly Report · 11/18 11:22
Vivani Medical Gains ‘Buy’ Rating Due to Strategic Advancements and Financial Strength
TipRanks · 11/14 15:25
Vivani Medical Reports Q3 Loss, Advances GLP-1 Trials
TipRanks · 11/14 04:34
Vivani Medical GAAP EPS of -$0.11
Seeking Alpha · 11/13 20:00
Vivani Medical Secures Funding for GLP-1 Implant Trial
TipRanks · 11/13 14:00
Vivani Medical Q3 2024 GAAP EPS $(0.11), Inline
Benzinga · 11/13 13:44
More
Webull provides a variety of real-time VANI stock news. You can receive the latest news about Vivani Medical through multiple platforms. This information may help you make smarter investment decisions.
About VANI
Vivani Medical, Inc. is a biopharmaceutical company developing novel, ultra-long-acting drug implants. Leveraging its NanoPortal platform, the Company develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Its lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of chronic weight management in obese or overweight individuals. Its pipeline also includes the NPM-139 (semaglutide) implant which is also under development for chronic weight management in obese and overweight individuals. NPM-119 refers to its Type II diabetes development program. OKV-119 is an exenatide implant that is under development for metabolic diseases in cats, including for the treatment of obesity and diabetes. Its segments include Biopharm Division and Neurostimulation Division.